03.08.16
Almac Group’s Diagnostics Business Unit has opened its new companion diagnostic development facility in the Research Triangle Park region of NC. This facility will provide a U.S. base to support Almac’s CDx development partnerships, as well as a CLIA-accredited lab to support the downstream delivery of assays for patient testing.
The custom designed facility is equipped with microarray and qPCR platforms appropriate for companion diagnostic development and will operate both research-use-only and clinical diagnostic tests. Plans are also in place to add additional technology platforms including NGS in the coming year.
“The opening of our new CDx facility in the U.S. is Almac Diagnostics’ latest initiative to better serve our global Biopharma partners. As we experience increased client demand for our companion diagnostic development services, this latest expansion will significantly enhance Almac’s offering, increasing capacity and further demonstrating our commitment to personalised healthcare,” said Professor Paul Harkin, president and managing director of Almac Diagnostics.
The custom designed facility is equipped with microarray and qPCR platforms appropriate for companion diagnostic development and will operate both research-use-only and clinical diagnostic tests. Plans are also in place to add additional technology platforms including NGS in the coming year.
“The opening of our new CDx facility in the U.S. is Almac Diagnostics’ latest initiative to better serve our global Biopharma partners. As we experience increased client demand for our companion diagnostic development services, this latest expansion will significantly enhance Almac’s offering, increasing capacity and further demonstrating our commitment to personalised healthcare,” said Professor Paul Harkin, president and managing director of Almac Diagnostics.
